Abivax S.A.

$120.34

$2.69(-2.18%)

Abivax S.A.

ABVX

$120.34

$2.69(-2.18%)

Abivax S.A.

ABVX

NASDAQ

$120.34

$2.69(-2.18%)

Chart

Upcoming Earnings

Next report date

Mar 23, 2026

Report period

Q1 2026

EPS Estimate

$-1.35

Revenue Estimate

$1.55M

Key stats

52-Week Range$120.34

$4.77

$148.83

Market capitalization

$8.05B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-31.67

Basic EPS (TTM)

$-5.72

Net income (TTM)

$-331.99M

Revenue (TTM)

$15.14M

Avg. volume

1.30M

Beta (1Y)

-0.38

Employees

Market capitalization

$8.05B

Dividend yield (indicated)

0.00%

Price to earnings Ratio (TTM)

-31.67

Basic EPS (TTM)

$-5.72

Net income (TTM)

$-331.99M

Revenue (TTM)

$15.14M

Avg. volume

1.30M

Beta (1Y)

-0.38

Employees

Screener Quick Check

About Abivax S.A.

Sector

Healthcare

Industry

Biotechnology

CEO

Marc de Garidel

Website

www.abivax.com

Headquarters

5, rue de la Baume, Paris, 75008

IPO Date

2023-10-20

Identifiers

ISINUS00370M1036

Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and...

Related Stocks

Jazz Pharmaceuticals plc

JAZZ

$182.02Mkt Cap: $11.21B

Healthcare

Biotechnology

ISIN:IE00B4Q5ZN47

Madrigal Pharmaceuticals, Inc.

MDGL

$440.83Mkt Cap: $10.01B

Healthcare

Biotechnology

ISIN:US5588681057

Dividend Overview

This company does not pay dividends

Financials

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q1 '26

Actual

Estimate

Earnings

Next: Q1 '26

Actual

Estimate

Performance

Margin trends

Debt level and coverage

Earnings

Next: Q1 '26

Actual

Estimate

Earnings

Next: Q1 '26

Actual

Estimate